Akèy › Karsinòm Nèwo-endokrin
Etid klinik pou Karsinòm Nèwo-endokrin ap rekrite nan Etazini
16 etid pou Karsinòm Nèwo-endokrin ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX6 etid
- New York City, NY6 etid
- Arlington, VA5 etid
- Dallas, TX4 etid
- Los Angeles, CA4 etid
- Washington, DC4 etid
- New Haven, CT3 etid
- Seattle, WA3 etid
- Columbus, OH3 etid
- Atlanta, GA3 etid
- Nashville, TN3 etid
- Grand Rapids, MI3 etid
- Denver, CO3 etid
- St. Louis, MO3 etid
Pa eta
- Colorado4 etid
- Connecticut3 etid
- Florid5 etid
- Georgia4 etid
- Kalifòni6 etid
- Lwizyàn3 etid
- Maryland6 etid
- Michigan3 etid
- Missouri3 etid
- New Jersey4 etid
- New York6 etid
- Ohio4 etid
- Tennessee4 etid
- Texas8 etid
- Virginia5 etid
- Washington4 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Ap rekriteFaz 2
Laj 18 a 120 · Tout sèks · Mizajou Oct 2, 2026 · NCT06406465Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Oct 2, 2026 · NCT07509034Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Sep 24, 2026 · NCT05237934Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07278479Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07080242A Study of Armored CAR T Cells in People With Cancer
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07783477A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT07488923A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06330064A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT07129252A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT05652686Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Ap rekriteFaz 1/2
Laj 18 a 99 · Tout sèks · Mizajou Jul 13, 2026 · NCT05000294A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2026 · NCT07174583A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Jun 15, 2026 · NCT06041516A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou May 27, 2026 · NCT03093116SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 28, 2026 · NCT06889493A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Dec 11, 2025 · NCT06943521Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.